Group 1 - Shouyao Holdings is planning to issue H-shares and list on the Hong Kong Stock Exchange, with discussions ongoing with intermediaries regarding the specifics of the listing [1] - Jiangsu Guoxin's subsidiary, Guoxin Mazhou, has completed the trial operation of a 1000MW coal-fired power unit, which is set to officially commence operations on December 12, 2025 [2] - Yuekang Pharmaceutical's mRNA tumor vaccine has received clinical trial approval from the National Medical Products Administration for treating advanced solid tumors [3] Group 2 - Dongli New Science plans to invest 666 million yuan in the restructuring of SAIC Hongyan, acquiring approximately 14.66% equity post-restructuring [4] - Longsheng Technology is set to invest approximately 350 million yuan in the establishment of an intelligent robot innovation center in Wuxi [5] - Shangwei Co. has received a government subsidy of 2.212 million yuan, which accounts for 13.53% of its audited net profit for 2024 [6] Group 3 - Anglikang has received drug registration certificates for Diclofenac Sodium Enteric-Coated Tablets and approval for a supplemental application for Sacubitril/Valsartan Sodium Tablets [7] - Guangzhou Development has received acceptance notices for the registration of 8 billion yuan in medium-term notes and 6 billion yuan in short-term financing bonds [8] - Kebo Da plans to increase capital by 21.2 million euros (approximately 174 million yuan) in its wholly-owned subsidiary in Germany [9][10] Group 4 - Changguang Huaxin has received a total of 11.6672 million yuan in government subsidies, including 8.0552 million yuan related to income [11] - Haizheng Pharmaceutical's subsidiary has received a European Pharmacopoeia suitability certificate for its raw material [12] - Qianjin Pharmaceutical's subsidiary has received a drug registration certificate for Lurasidone Hydrochloride Tablets, used for treating schizophrenia [13] Group 5 - Daimai Co. has received a warning letter from the Shanghai Securities Regulatory Bureau due to failure to timely disclose a significant event related to a fire incident [14] - ST Changyao's subsidiary has recently ceased production due to financial difficulties and competitive pressures in the photovoltaic industry [15] - Guodian Power is investing in the construction of a 2×1000MW expansion project at the Ganbi Power Plant, with a total dynamic investment of 7.218 billion yuan [16] Group 6 - Kaichuang International's subsidiary has completed the handover of a tuna purse seine vessel, expected to be operational by 2026 [16] - Tieke Rail plans to sign an energy management agreement for a distributed photovoltaic project, which is expected to save approximately 1.441 million yuan in electricity costs over 25 years [18] - Bailian Co. plans to sign a land compensation agreement with Friendship Logistics, with a total compensation of 103 million yuan [19] Group 7 - Dayu Water-saving's subsidiary has been pre-awarded two high-standard farmland construction projects, with total expected amounts of 137 million yuan and 135 million yuan respectively [20] - Tianma Technology reported a total eel output of approximately 1197.15 tons in November, with sales prices ranging from 53,000 yuan/ton to 89,000 yuan/ton [21] - Guorui Technology's subsidiary has been shortlisted for the GXLF project with a bid of 76 million yuan [22] Group 8 - Qingdao Food's deputy general manager has resigned for personal reasons [23] - Guosheng Zhike plans to use up to 900 million yuan of idle funds for cash management [24] - Guodian Nanrui plans to use up to 23 billion yuan of idle funds for entrusted wealth management [25] Group 9 - Jiahuan Energy plans to merge its wholly-owned subsidiary, Zhejiang Jiahuan Hydrogen Peroxide Co., Ltd., through an overall absorption merger [26] - Ganyue Expressway reported vehicle toll service revenue of 309 million yuan for November [27] - Jinling Hotel's chairman has resigned due to work changes [28] Group 10 - Lisheng Pharmaceutical's subsidiary has received drug registration certificates for Apremilast Tablets [29] - Baotai has received a positive opinion from the European Medicines Agency for Gotenfia® for various inflammatory conditions [30] - ST Zhisheng has been awarded a smart city governance project with a bid amount of 104 million yuan [31] Group 11 - Chenxi Aviation and its related personnel have received administrative regulatory measures from the Shaanxi Securities Regulatory Bureau due to financial reporting issues [32] - Portong Medical has appointed Xia Canglan as the new deputy general manager [33] - Maide Medical plans to repurchase shares with a total amount between 20 million and 40 million yuan [34] Group 12 - Jimin Health plans to establish a joint venture with a total investment of 600 million yuan, focusing on AI and software development [35] - Beilu Pharmaceutical has received a drug registration certificate for Pioglitazone Metformin Tablets [36] - Hainan Mining plans to entrust the overall management of the Shiluo Iron Mine to a construction company for three years, with a total contract amount of approximately 818 million yuan [38] Group 13 - Huiyu Pharmaceutical has received a drug registration certificate for Nicardipine Hydrochloride Injection [39] - Baoland has received a government subsidy of 10 million yuan related to income [40] - Qingdao Port has terminated the acquisition of 100% equity in an oil company and 50% equity in Rizhao Shihua due to regulatory concerns [41]

智通财经APP讯，首药控股(688197.SH)发布公告，公司为进一步提升核心竞争力与品牌影响力，充分 借助国际资本市场的资源与机制优势，优化资本结构，拓宽多元融资渠道，正在筹划发行境外股份(H 股)并在香港联合交易所有限公司(以下简称"香港联交所")上市事宜。 ...

首药控股(688197.SH)发布公告，公司为进一步提升核心竞争力与品牌影响力，充分借助国际资本市场 的资源与机制优势，优化资本结构，拓宽多元融资渠道，正在筹划发行境外股份(H股)并在香港联合交 易所有限公司(以下简称"香港联交所")上市事宜。 ...

证券代码：688197 证券简称：首药控股 公告编号：2025-030 首药控股（北京）股份有限公司董事会 2025年12月13日 2 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 本次发行H股并上市能否通过审议、备案和审核程序并最终实施存在较大 不确定性，敬请广大投资者理性投资，注意投资风险。 特此公告。 首药控股（北京）股份有限公司 关于筹划境外发行股份（H股）并在香港联合交易所有限公 司上市相关事项的提示性公告 1 首药控股（北京）股份有限公司（以下简称"公司"）为进一步提升核心 竞争力与品牌影响力，充分借助国际资本市场的资源与机制优势，优化资本结 构，拓宽多元融资渠道，正在筹划发行境外股份（H股）并在香港联合交易所 有限公司（以下简称"香港联交所"）上市事宜（以下简称"本次H股上 市"）。公司正与中介机构就本次H股上市的具体推进工作进行商讨，相关细 节尚未确定。本次H股上市不会导致公司控股股东和实际控制人发生变化。 根据《中华人民共和国证券法》《上海证券交易所科创板股票上市规则》 《境内企业境外发行证券和上市管 ...

格隆汇12月12日丨首药控股(688197.SH)公布，公司为进一步提升核心竞争力与品牌影响力，充分借助 国际资本市场的资源与机制优势，优化资本结构，拓宽多元融资渠道，正在筹划发行境外股份(H股)并 在香港联合交易所有限公司(以下简称"香港联交所")上市事宜(以下简称"本次H股上市")。公司正与中介 机构就本次H股上市的具体推进工作进行商讨，相关细节尚未确定。本次H股上市不会导致公司控股股 东和实际控制人发生变化。 ...

南方财经12月12日电，首药控股12月12日公告，正在筹划发行境外股份（H股）并在香港联合交易所有 限公司上市事宜。公司正与中介机构就本次H股上市的具体推进工作进行商讨，相关细节尚未确定。本 次H股上市不会导致公司控股股东和实际控制人发生变化。待确定具体方案后，本次H股上市工作尚需 提交公司董事会及股东会审议，并需取得中国证券监督管理委员会、香港联交所和香港证券及期货事务 监察委员会等监管机构的备案、批准或者核准。 ...

人民财讯12月12日电，首药控股(688197)12月12日公告，公司正在筹划发行H股股份并在香港联交所上 市事宜。公司正与中介机构就本次H股上市的具体推进工作进行商讨，相关细节尚未确定。本次H股上 市不会导致公司控股股东和实际控制人发生变化。 转自：证券时报 ...

2025年前三季度，公司实现营业收入200万元，同比下滑47.37%；归属于上市公司股东的净利 润-1.55亿元；归属于上市公司股东的扣除非经常性损益的净利润-1.69亿元；经营活动产生的现金流量 净额为-1.72亿元。 | | | 本报告期比 上年同期增 | | 年初至报告期 末比上年同期 | | --- | --- | --- | --- | --- | | 项目 | 本报告期 | | 年初至报告期末 | | | | | 减变动幅度 | | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | | 不适用 | 2,000,000.00 | -47.37 | | 利润总额 | -50.395.389.71 | 不适用 | -154.767.127.09 | 不适用 | | 归属于上市公司股东的 | -50,395,389.71 | 不适用 | -154.767.127.09 | 不适用 | | 净利润 | | | | | | 归属于上市公司股东的 扣除非经常性损益的净 | -54,587,829.93 | 不适用 | -168.841.741.16 | 不适用 | | 利润 | | | ...

Investment Rating - The investment rating for the industry is "Positive" and the rating has been maintained [2] Core Views - The pharmaceutical and biotechnology industry index experienced a decline of 4.40%, ranking 23rd among 31 primary industries, underperforming the CSI 300 index which fell by 2.19% [6][18] - The valuation of the pharmaceutical and biotechnology industry as of November 28, 2025, is a PE (TTM overall method, excluding negative values) of 29.46x, down from 30.89x in the previous period, indicating a downward trend and below the average [22] - The report highlights potential beneficiaries from the upcoming ASH data, particularly in blood diseases and companies with solid grassroots channels, as well as those with differentiated advantages in oncology, autoimmune, and rare disease products [10] Summary by Sections Industry Review - The pharmaceutical and biotechnology industry index fell by 4.40%, with chemical preparations and medical devices showing declines of 2.86% and 2.95% respectively, while offline pharmacies and vaccines saw larger declines of 8.22% and 6.42% [6][18] - The PE ratio for the pharmaceutical and biotechnology industry is 29.46x, with the highest valuations in the vaccine (47.56x), hospital (41.17x), and medical device (36.77x) sectors, while pharmaceutical circulation has the lowest at 14.58x [22] Important Industry News - The National Administration of Traditional Chinese Medicine and the National Healthcare Security Administration released a directory for traditional Chinese medicine diseases suitable for disease-based payment [26][27] - AstraZeneca's drug "Durvalumab" received FDA approval for a new indication in perioperative treatment of gastric cancer [32] - Otsuka Pharmaceutical's new drug for IgA nephropathy, "Sibeprenlimab," has been approved by the FDA [38] - Bayer's first-in-class lung cancer drug "Sevabertinib" has been approved by the FDA for specific patient populations [40] Investment Recommendations - Focus on innovative pharmaceutical companies that may benefit from the medical insurance or commercial insurance directories, blood cancer targets with imminent ASH data releases, and biotech and CXO leaders with solid technology platforms and international collaboration expectations [10]

（文章来源：每日经济新闻） 首药控股（688197.SH）11月27日在投资者互动平台表示，康太替尼颗粒（SY-707）新药上市审评工作 目前正在有序推进。其商业化表现敬请关注公司后续披露的定期报告及财务数据。 每经AI快讯，有投资者在投资者互动平台提问：贵司的新药康泰替尼，自从8月上旬后在国家药品评审 中心已经查询不到排队信息，请问相关的进度信息如何，是否已经获批，如果获批对企业的未来经营预 计会产生哪些影响？ ...